Dermira (DERM) Stock Rating Reaffirmed by Guggenheim
Dermira (NASDAQ:DERM)‘s stock had its “buy” rating restated by investment analysts at Guggenheim in a research report issued to clients and investors on Thursday. They currently have a $30.00 target price on the biopharmaceutical company’s stock. Guggenheim’s price target points to a potential upside of 10.86% from the company’s previous close.
Several other equities analysts have also recently issued reports on DERM. BidaskClub upgraded shares of Dermira from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Mizuho restated a “buy” rating and set a $43.00 target price (up previously from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Dermira in a research note on Sunday, September 17th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $45.00 target price on shares of Dermira in a research note on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Dermira presently has an average rating of “Hold” and a consensus target price of $41.00.
Dermira (NASDAQ DERM) opened at $27.06 on Thursday. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira has a one year low of $21.35 and a one year high of $38.75.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AXA increased its position in shares of Dermira by 41.5% during the 3rd quarter. AXA now owns 300,333 shares of the biopharmaceutical company’s stock valued at $8,109,000 after purchasing an additional 88,079 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Dermira in the 3rd quarter worth approximately $696,000. Point72 Asset Management L.P. increased its holdings in Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after acquiring an additional 614,138 shares in the last quarter. Alyeska Investment Group L.P. increased its holdings in Dermira by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 351,059 shares of the biopharmaceutical company’s stock worth $9,479,000 after acquiring an additional 6,270 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its holdings in Dermira by 60.1% in the 3rd quarter. Platinum Investment Management Ltd. now owns 92,400 shares of the biopharmaceutical company’s stock worth $2,494,000 after acquiring an additional 34,700 shares in the last quarter. 99.54% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/dermira-derm-stock-rating-reaffirmed-by-guggenheim/1766870.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.